Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants - Wikidata - wikimedia - TriplyDB

Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants

Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants

http://www.wikidata.org/entity/Q26996955

about

Biological predictors of pharmacological therapy in anxiety disorders Intermediate phenotypes and biomarkers of treatment outcome in major depressive disorder The neuroscience of depression: implications for assessment and intervention.Increased fear-potentiated startle in major depressive disorder patients with lifetime history of suicide attempt In pursuit of neuroimaging biomarkers to guide treatment selection in major depressive disorder: a review of the literature.Animal models to improve our understanding and treatment of suicidal behavior Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety.Pharmacologic treatment of dimensional anxious depression: a review Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review.Attachment Style Moderates the Effects of Oxytocin on Social Behaviors and Cognitions During Social Rejection: Applying an RDoC Framework to Social Anxiety.Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression.Assessment of non-BDNF neurotrophins and GDNF levels after depression treatment with sertraline and transcranial direct current stimulation in a factorial, randomized, sham-controlled trial (SELECT-TDCS): an exploratory analysis.Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.Shank3 as a potential biomarker of antidepressant response to ketamine and its neural correlates in bipolar depression Cortical abnormalities and association with symptom dimensions across the depressive spectrum.Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine.Ketamine: translating mechanistic discoveries into the next generation of glutamate modulators for mood disorders.The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder.The dysregulated brain: consequences of spatial and temporal brain complexity for bipolar disorder pathophysiology and diagnosis.Glutamatergic Modulators in Depression.

P2860

Q26781100-342E35E6-CCDD-46AF-A25D-2722B9D93017 Q26823991-96937804-14F8-42C5-89A5-272267D36244 Q30399725-7EC75779-C841-49A9-B2F3-CBE09DE94DBB Q30410311-507FAECF-BBEB-4FD0-BB73-409700379FD4 Q30927398-029EFAD6-BB86-4F71-945A-FAA0D81DD093 Q33635653-FED2D042-8BD3-4EFE-ADB8-2146AF2141DD Q34177760-55296273-4FAE-46AA-A239-5A502757BB54 Q34331887-C3316710-30FC-44DD-8BC3-B7D1B65BC288 Q34475595-66BBA758-5A8A-439B-9EA9-BE0C49561F42 Q34549329-A127C21A-66B4-4E5A-A3D6-D46CD06BF4AB Q34551188-7657505D-E92E-45B8-9030-5BE72507C907 Q34647315-07B06049-DDED-4DD3-B67D-DCE63852FC37 Q35001345-A4322B23-87DF-43D4-9778-1C79EE97E122 Q35449610-A7A81623-EF00-4B48-829B-36A0C650E5DB Q36609012-97DEF9A9-08C0-480C-9E87-B34A727656ED Q38838637-83071B0F-32D9-4CF1-97E7-4CD4F1A70C79 Q42253326-A51E0558-8744-4330-852F-85B4DE14D8B6 Q47595593-596BACD4-5E42-47C4-830A-9C49CEC6C21B Q48135944-56B06CEC-0475-47A6-896B-29FC64770A35 Q49712849-06C25AA3-44F6-44BC-8304-EAAD11E86AF7

P2860

Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants

http://www.wikidata.org/entity/Q26996955

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Developing biomarkers in mood ...... f rapid-acting antidepressants

@ast

Developing biomarkers in mood ...... f rapid-acting antidepressants

@en

Developing biomarkers in mood ...... f rapid-acting antidepressants

@nl

type

label

Developing biomarkers in mood ...... f rapid-acting antidepressants

@ast

Developing biomarkers in mood ...... f rapid-acting antidepressants

@en

Developing biomarkers in mood ...... f rapid-acting antidepressants

@nl

prefLabel

Developing biomarkers in mood ...... f rapid-acting antidepressants

@ast

Developing biomarkers in mood ...... f rapid-acting antidepressants

@en

Developing biomarkers in mood ...... f rapid-acting antidepressants

@nl

P1433

Q26996955-ED1C8C7A-F437-4CB4-934D-E99B8D37AB28

P1476

Q26996955-89A2F839-2D09-4FF0-AEE6-30A2BA496E0B

P2093

Q26996955-07106CE2-2303-43CD-AB5C-D9805D178B6A

Q26996955-8B27F74C-2C33-4A86-AE94-E0C182785BCF

Q26996955-94062D2C-EFCE-497D-B144-30F1D0870C4C

Q26996955-95FCCB4A-238F-4DF0-B3E3-00A3B2C69A23

Q26996955-C99FFF73-AE02-416F-95F2-2FD37E62DB9C

P2860

Q26996955-0A268CD2-156D-4E1A-83B8-CA743FF94379

Q26996955-0AF42AB8-8F06-4A46-A9AA-D4B9FC265F09

Q26996955-1375BC33-FAAB-4FD6-900B-111DED655FA4

Q26996955-162F6A81-2171-49D3-879E-40AE4403F353

Q26996955-170E0109-D1C2-4B32-982E-45E95AE25322

Q26996955-1DBF2D57-6110-404D-B65F-882EFFBF125E

Q26996955-1E6E76CE-9181-4217-AAC6-D775A43076DB

Q26996955-285FECAE-3DBF-4B21-86D1-BD5759A241A5

Q26996955-368D5E03-7F4E-466C-9970-4C84997EF217

Q26996955-41AD9DB7-B3C5-4B6A-BC95-D48C9C1701C6

P304

Q26996955-68CAD3F8-FC1C-4011-9397-D0E6D3B56DDB

P31

Q26996955-0C4071B1-6531-4CBF-A805-7C58286E7D78

P356

Q26996955-6443E57C-EA00-43CD-B678-9DA41CD005FA

P407

Q26996955-4FDE56E7-04DC-43C4-A39B-2C2524AEA492

P433

Q26996955-361A120A-5DE1-4416-956A-AC0F951268CA

P478

Q26996955-DCA81AD6-C03E-4397-83AA-63071A76A4A2

P50

Q26996955-5292514C-4619-4225-B657-7818AAC6F58D

Q26996955-6F15E3A3-3D09-46AF-859A-A4A48F36F7AD

Q26996955-759B948D-83D3-4C5C-8406-D26AA02AAFAE

P577

Q26996955-86D6061C-7595-4892-9FA1-2835F82C6B3A

P5875

Q26996955-2760CFA7-8F22-4254-B7DC-4B33197A63FE

P698

Q26996955-A52E0FD8-CE6B-4D4E-9B5B-0EA6497F868D

P921

Q26996955-05894BE4-660D-406B-B87C-CDA4DDDCF5C3

P932

Q26996955-D90DCB8B-B9CA-4058-A56B-18EB51F08288

P356

P1433

Depression and Anxiety

P1476

Developing biomarkers in mood ...... f rapid-acting antidepressants

@en

P2093

Carlos A Zarate

http://www.w3.org/2001/XMLSchema#string

Daniel C Mathews

http://www.w3.org/2001/XMLSchema#string

Dawn F Ionescu

http://www.w3.org/2001/XMLSchema#string

Erica M Richards

http://www.w3.org/2001/XMLSchema#string

Maura L Furey

http://www.w3.org/2001/XMLSchema#string

P2860

Neuroimaging in psychiatric pharmacogenetics research: the promise and pitfalls

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

Data sharing in neuroimaging research

Systems biology: a brief overview

Research domain criteria (RDoC): toward a new classification framework for research on mental disorders

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists

Surrogate outcomes in neurology, psychiatry, and psychopharmacology

Acute hydrocortisone treatment increases anxiety but not fear in healthy volunteers: a fear-potentiated startle study.

P304

297-307

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/DA.22224

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

Allison C. Nugent

Rodrigo Machado-Vieira

P577

2013-12-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259387701

http://www.w3.org/2001/XMLSchema#string

P698

24353110

http://www.w3.org/2001/XMLSchema#string

P921

P932

3984598

http://www.w3.org/2001/XMLSchema#string